Kazia Therapeutics Ltd · NASDAQ:KZIA
Kazia Therapeutics — Investor Presentation (November 2024)
37 slides from Kazia Therapeutics's investor presentation, November 2024
Slide 1: A Diversified Oncology Drug Development Company
A Diversified Oncology Drug Development Company Kazia Corporate Overview November 2024 NASDAQ: KZIA | X: @KaziaTx
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward -looking statements, which can generally be identified as such by the use of words such as “may,” “will,” “estimate,” “future,” “forward,” “anticipate,” “plan,” “expect,” “explore,” “potential” or other similar words. Any statement descri
Slide 3: Company Overview
Company Overview A late-clinical-stage oncology drug development company Corporate Highlights Licensing-driven business model Paxalisib EVT801 focused on high quality, differentiated clinical-stage assets sourced from Genentech (Paxalisib) and Sanofi / Brain-penetrant pan-PI3K / mTOR inhibitor Selec
Slide 4: Pipeline – Two Differentiated Assets
Pipeline – Two Differentiated Assets CY2024 positive clinical data updates driving strong interest in oncology community Paxalisib licensed from: Investigational, small molecule, potent, brain-penetrant inhibitor of PI3K / mTOR Preclinical PHASE 1 PHASE 2 PHASE 3 MARKET Collaborators / Sponsors Anti
Slide 5: Paxalisib Mechanism of Action
Paxalisib Mechanism of Action Only brain-penetrant drug in development within the PI3K inhibitor class 1 The PI3K pathway is activated in 2 Five PI3K inhibitors have already 3 Paxalisib is the only brain-penetrant many forms of cancer been approved by FDA PI3K inhibitor in development • Chronic lymp
Slide 6: Paxalisib – Development History
Paxalisib – Development History Growing Body of Clinical Evidence Demonstrating Activity in GBM 2012-2015 February 2018 August 2019 7 January 2021 1 August 2022 Genentech Phase I clinical GDC-0084 awarded GDC-0084 becomes GBM AGILE Kazia provides progress study in 47 patients with Orphan Drug Design
Slide 7: Glioblastoma Background & Market potential
Glioblastoma Background & Market potential 6
Slide 8: Glioblastoma Overview
Glioblastoma Overview The most aggressive malignant brain cancer Lung No clear Any age, No clear but most improvement in cause common in prognosis for Breast or strong risk factors 60s 20 years 14 million cancer cases per annum Colon 3-4 months Five-year survival Prostate Stomach Survival, 3 – 5% if
Slide 9: Primary Market Research Outcomes
Primary Market Research Outcomes Physicians indicated a 2-month minimum and 12-month optimum increase in efficacy for newly diagnosed unmethylated GBM treatments, but adoption would be high regardless Key Takeaway • Due to the high unmet need for a more efficacious therapy for Newly Diagnosed Unmeth
Slide 10: GBM AGILE study data – Primary and secondary analysis
GBM AGILE study data – Primary and secondary analysis 9
Slide 11: Randomization and GBM-Agile
Paxalisib and GBM-Agile International, multi-center, adaptive, phase 2/3 study evaluating promising therapeutics in patients with glioblastoma Key Points Regorafenib Completed Negative outcome Bayer (Sep 2022) • A ‘platform study’, sponsored by GCAR run independently of Paxalisib 3 Final Top Line in
Slide 12: Paxalisib & GBM-Agile
Paxalisib & GBM-Agile Study schema; Paxalisib arm (n=154) enrolled Newly Diagnosed Unmethylated GBM patients (NDU) and Recurrent GBM patients Paxalisib Paxalisib stage 1 stage 2 Evaluate for graduation Evaluate for futility Paxalisib Study completed enrolment stops 12 months after last patient enrol
Slide 13: Paxalisib and GBM-Agile
Paxalisib and GBM-Agile Newly Diagnosed Unmethylated GBM patients (NDU) Primary endpoint: median Overall Survival analyses (ITT) Bayesian Primary Analysis: Prespecified Secondary Analysis: Paxalisib (n=54) vs Standard of Care Paxalisib (n=54) vs Standard of Care (n=77)1 (n=46)2 14.77 months vs 13.84
Slide 14: Recap and next steps for Paxalisib in glioblastoma
Recap and next steps for Paxalisib in glioblastoma 13
Slide 15: Paxalisib in Glioblastoma Phase II Clinical Study
Paxalisib in Glioblastoma Phase II Clinical Study Encouraging median OS (mOS) in Newly Diagnosed Unmethylated GBM patients Overall Survival (OS) (n=30) Median OS: 15.7 months (11.1-19.1) Historical mOS for existing therapy: 12.7 months (Hegi et al. 2005) Note: Figures for existing therapy are for te
Slide 16: Paxalisib in Glioblastoma Phase II Clinical Study
Paxalisib in Glioblastoma Phase II Clinical Study Encouraging safety profile Number of Patients at Any Dose (n=30) Experiencing AEs ‘Possibly’ or ‘Likely’ Related to Paxalisib (affecting ≥10% of patients) Term Gr 1 Gr 2 Gr 3 Gr 4 Total (%) Fatigue 3 13 2 18 (60%) Stomatitis 4 7 3 14 (47%) Decreased
Slide 17: Paxalisib in Glioblastoma
Paxalisib in Glioblastoma Consistent median Overall Survival data in two studies of NDU glioblastoma patients Standard of Care data GBM AGILE study (left) Compelling Paxalisib data in NDU patients and STUPP historical controls (right) in NDU when compared to SOC patients Paxalisib in Paxalisib in Co
Slide 18: Paxalisib glioblastoma program highlights
Paxalisib glioblastoma program highlights Significant body of clinical evidence from two clinical trials supporting paxalisib’s activity in newly diagnosed GBM ✓ GBM AGILE Phase II/III trial data showed improvement in a prespecified secondary analysis for overall survival (15.5 months) in paxalisib-
Slide 19: Childhood Brain Cancers
Childhood Brain Cancers 18
Slide 20: Paxalisib in Childhood Brain Cancer
Paxalisib in Childhood Brain Cancer High unmet need especially in patients with diffuse midline gliomas (DMGs) 1 Brain cancer is the most common 2 Brain cancer represents about one 3 Prognosis of childhood brain malignancy of childhood third of childhood cancer deaths cancer, especially DMGs, has im
Slide 21: Summary of Paxalisib in Childhood Brain Cancer
Summary of Paxalisib in Childhood Brain Cancer Kazia is actively pursuing three forms of childhood brain cancer Diffuse Midline Gliomas Atypical Teratoid / Advanced Childhood Cancer (DMG, DIPG) Rhabdoid Tumors (AT/RT) (PI3K/mTOR activated) Positive preclinical data as Preclinical Positive preclinica
Slide 22: Paxalisib in Diffuse Midline Gliomas
Paxalisib in Diffuse Midline Gliomas Follow-up Phase II data presented at ISPNO 2024 Annual Meeting In spite of research that has helped improve treatment for DIPG patients, the prognosis remains poor–with the median survival range being from 8-11 months1 • 68 patients with biopsy-proven DMG were en
Slide 23: Brain Metastases
Brain Metastases 22
Slide 24: Paxalisib in Brain Metastasis
Paxalisib in Brain Metastasis MSKCC-sponsored Phase I trial’s interim analysis showed encouraging clinical activity of paxalisib in combination with radiation therapy (NCT04192981) 12-13 August 2022 July 2023 February 2024 Data from first stage presented at Fast Track Designation granted by Announce
Slide 25: Paxalisib in Brain Metastasis: 2024 ASTRO interim analysis
Paxalisib in Brain Metastasis MSKCC-sponsored Phase I trial’s interim analysis presented at 2024 ASTRO* meeting showed encouraging clinical activity of paxalisib in combination with radiation therapy (NCT04192981) Robust response signal seen for concurrent paxalisib and brain RT Overall Summary • Pr
Slide 26: Other Solid Tumors
Other Solid Tumors 25
Slide 27: Paxalisib in Triple Negative Breast Cancer
Paxalisib in Triple Negative Breast Cancer QIMR Berghofer Medical Institute collaboration “In treatment-resistant pre-clinical models of breast cancer, paxalisib (4T1 mouse model, TNBC1) has shown encouraging results in inhibiting both the primary tumor burden and metastasis by reinvigorating the im
Slide 28: Triple Negative Breast Cancer Treatment Landscape
Triple Negative Breast Cancer Treatment Landscape Projected TNBC market to exceed $1.5 Billion by 2030 2.3 million1 American Triple negative Cancer Society breast cancer TNBC market growth forecast2 Cases / year says nearly Breast cancer TNBC USD $1.5b most commonly 300,000 most aggressive diagnosed
Slide 29: EVT801
EVT801 28
Slide 30: EVT801 is a highly selective VEGFR3 inhibitor
EVT801 is a highly selective VEGFR3 inhibitor, primarily inhibiting lymphangiogenesis (formation of new lymphatic vessels) Highly selective for VEGFR3 Expected to minimise off-target toxicities Oral Presentation Administered by mouth once or twice daily Strong IP Protection Inhibits lymphangiogenesi
Slide 31: EVT801 Mechanism of Action
EVT801 Mechanism of Action By targeting VEGFR3pos tumor blood vessels, EVT801 may induce tumor blood vessel normalization, reduce hypoxia, and improve CD8 T-cells infiltration Schematic overview based on pre-clinical data EVT801 activity on tumor microenvironment Tumor metastasis Normalization of tu
Slide 32: EVT801: Phase 1 dose-finding trial
EVT801: Phase 1 dose-finding trial; KZA 0801-101 (NCT05114668) Staged development in patients with advanced cancer l a i t n e d i f n Phase 1 study in advanced cancer patients Completed STAGE 1 • Primary objective of stage one of the study was successfully Monotherapy dose escalation met: n<48 o MT
Slide 33: EVT801 Key Points
EVT801 Key Points 1 Well-understood mechanism (anti-angiogenesis) with unique differentiating feature (high VEGFR3 selectivity) 2 Strong preclinical data package, with observed activity in multiple tumours and favourable toxicology 3 Potential for combination use with immuno-oncology therapies 4 Pha
Slide 34: 2024 Corporate Update
2024 Corporate Update 33
Slide 35: Paxalisib Licensing and Collaborations
Paxalisib Licensing and Collaborations Opportunistic partnering and strategic collaborations continue to add value Licensing Key Collaborations Summary To develop, manufacture and commercialize To develop and Paxalisib as a potential Cutting edge preclinical program to evaluate Territories and comme
Slide 36: Kazia Therapeutics: 2024-2025 Corporate Focus
Kazia Therapeutics: 2024-2025 Corporate Focus Objectives for value creation • Compile data from all clinical trials Progress paxalisib • FDA granted Type C meeting with Kazia in December 2024 glioblastoma program • Propose potential pathways to registration Execute paxalisib • PNOC team to complete
Slide 37: www.kaziatherapeutics.com
www.kaziatherapeutics.com info@kaziatherapeutics.com
Kazia Therapeutics — Investor Presentation (November 2024) on 6ix